270 related articles for article (PubMed ID: 7743614)
1. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
[TBL] [Abstract][Full Text] [Related]
2. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
[TBL] [Abstract][Full Text] [Related]
3. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Jukema JW; Zwinderman AH; van Boven AJ; Reiber JH; Van der Laarse A; Lie KI; Bruschke AV
Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):425-30. PubMed ID: 8630669
[TBL] [Abstract][Full Text] [Related]
5. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW; van Boven AJ; Groenemeijer B; Zwinderman AH; Reiber JH; Bruschke AV; Henneman JA; Molhoek GP; Bruin T; Jansen H; Gagné E; Hayden MR; Kastelein JJ
Circulation; 1996 Oct; 94(8):1913-8. PubMed ID: 8873668
[TBL] [Abstract][Full Text] [Related]
6. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
[TBL] [Abstract][Full Text] [Related]
7. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group.
Barth JD; Zonjee MM
Can J Cardiol; 1992 Nov; 8(9):925-32. PubMed ID: 1486543
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
10. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
11. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS).
Aengevaeren WR; Uijen GJ; Jukema JW; Bruschke AV; van der Werf T
Circulation; 1997 Jul; 96(2):429-35. PubMed ID: 9244208
[TBL] [Abstract][Full Text] [Related]
12. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
[TBL] [Abstract][Full Text] [Related]
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
Sacks FM; Pfeffer MA; Moye LA; Rouleau JL; Rutherford JD; Cole TG; Brown L; Warnica JW; Arnold JM; Wun CC; Davis BR; Braunwald E
N Engl J Med; 1996 Oct; 335(14):1001-9. PubMed ID: 8801446
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
[TBL] [Abstract][Full Text] [Related]
17. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
de Groot E; Jukema JW; Montauban van Swijndregt AD; Zwinderman AH; Ackerstaff RG; van der Steen AF; Bom N; Lie KI; Bruschke AV
J Am Coll Cardiol; 1998 Jun; 31(7):1561-7. PubMed ID: 9626835
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
19. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
[TBL] [Abstract][Full Text] [Related]
20. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
